Collectively, our observations indicate that therapeutic modulation of peripheral GPR55 activity may provide a means for countering obesity-linked metabolic dysfunction and insulin resistance and improving the metabolic status of such tissues. This evidence concerns the gene GPR55 and obesity due to melanocortin 4 receptor deficiency.